{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.3","upperLimit":"4.2","value":"1.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"}],"units":"Participants"}],"description":"Progression-free survival is the period of time from study entry to time of disease progression, death or date of last contact, whichever occurs first. Progression is assessed by RECIST 1.1","dispersionType":"95% Confidence Interval","groups":[{"description":"Ixabepilone administered at 40 mg/m2 IV infusion over 3 hours on day 1 of a 21-day cycle until disease progression or adverse effects prohibit further treatment","id":"OG000","title":"Ixabepilone"}],"paramType":"MEDIAN","populationDescription":"Eligible and Treated Patients","reportingStatus":"POSTED","timeFrame":"From study entry to disease progression, death or date of last contact, whichever occurs first, up to 5 years of follow-up.","title":"Progression-free Survival","type":"SECONDARY","unitOfMeasure":"months"}